Roy van der Meel is an Assistant Professor at the dept of Biomedical Engineering of the Delft University of Technology (Netherlands) and the head of the Precision Medicine group under direction of Prof. Willem Mulder. His group’s research is focused on developing nanotherapeutics to regulate the immune response in a highly precise manner. Roy studied Biomedical Sciences and Drug Innovation at Utrecht University (Netherlands) where he obtained his M.Sc. degree in 2009. In 2013 he obtained his PhD degree at the Pharmaceutics Department of Utrecht University (Netherlands) under supervision of Prof.Dr.Gert Storm and Prof.Dr. Wim Hennink. Roy's research focused on developing nanomedicines to inhibit tumor growth and angiogenesis. After obtaining Marie Skłodowska-Curie Action funding from the European Commission and a Veni grant from the Netherlands Organization for Scientific Research, Roy conducted postdoctoral research in the labs of Dr. Raymond Schiffelers (University Medical Center Utrecht, Netherlands) and Dr. Pieter Cullis (University of British Columbia, Vancouver, BC, Canada). In 2019, Roy was appointed Assistant Professor at Eindhoven University (Netherlands).